MVA-C with gp140/MF59(HIV Vaccine Trials Network)(MVA-C with gp140/MF59(HIV Vaccine Trials Network))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

HIV感染

原研机构

HIV Vaccine Trials Network

在研机构-

非在研机构

HIV Vaccine Trials Network

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的临床试验

NCT01418235 / Completed临床1期IIT

A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis Subtype C gp140 With MF59 Adjuvant in Various Vaccination Schedules in HIV-uninfected Healthy Vaccinia-naïve Adult Participants in South Africa

Sub-Saharan Africa is the region most affected by the global Human Immunodeficiency Virus (HIV) epidemic. A vaccine is the most promising preventive approach against new HIV infections. The purpose of this study is to evaluate the safety and immunogenicity of 4 experimental preventive HIV vaccine regimens in HIV-uninfected adults in South Africa.

开始日期2011-12-19

申办/合作机构

HIV Vaccine Trials Network

100 项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的临床结果

登录后查看更多信息

100 项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的转化医学

登录后查看更多信息

100 项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的专利（医药）

登录后查看更多信息

100 项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的药物交易

登录后查看更多信息